Alimera Sciences (ALIM) Upgraded to Hold at Zacks Investment Research
Zacks Investment Research upgraded shares of Alimera Sciences (NASDAQ:ALIM) from a sell rating to a hold rating in a report published on Monday.
According to Zacks, “Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes these diseases are not well treated with current therapies and represent a significant market opportunity. Its product candidate Iluvien(R) is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. “
ALIM has been the subject of several other research reports. ValuEngine lowered Alimera Sciences from a sell rating to a strong sell rating in a report on Monday, September 18th. HC Wainwright reissued a buy rating and set a $5.00 price target on shares of Alimera Sciences in a report on Wednesday, November 22nd. Finally, Cowen reissued a buy rating on shares of Alimera Sciences in a report on Thursday, November 2nd. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. The stock presently has an average rating of Hold and an average target price of $3.38.
Alimera Sciences (NASDAQ ALIM) traded down $0.03 during trading hours on Monday, reaching $1.29. The company’s stock had a trading volume of 130,582 shares, compared to its average volume of 140,100. Alimera Sciences has a twelve month low of $1.11 and a twelve month high of $1.72. The company has a quick ratio of 4.65, a current ratio of 4.84 and a debt-to-equity ratio of -0.71. The company has a market capitalization of $88.87, a price-to-earnings ratio of -4.16 and a beta of 2.15.
A hedge fund recently raised its stake in Alimera Sciences stock. Stonepine Capital Management LLC lifted its holdings in Alimera Sciences, Inc. (NASDAQ:ALIM) by 158.2% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 477,226 shares of the biopharmaceutical company’s stock after acquiring an additional 292,399 shares during the period. Alimera Sciences accounts for about 0.4% of Stonepine Capital Management LLC’s portfolio, making the stock its 21st biggest holding. Stonepine Capital Management LLC owned approximately 0.69% of Alimera Sciences worth $644,000 as of its most recent SEC filing. Institutional investors and hedge funds own 41.78% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Alimera Sciences (ALIM) Upgraded to Hold at Zacks Investment Research” was originally reported by Daily Political and is the property of of Daily Political. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://www.dailypolitical.com/2018/01/09/alimera-sciences-alim-upgraded-to-hold-at-zacks-investment-research.html.
About Alimera Sciences
Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.